Compare ACHV & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACHV | PACB |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.5M | 655.9M |
| IPO Year | 2018 | 2010 |
| Metric | ACHV | PACB |
|---|---|---|
| Price | $6.80 | $2.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $14.15 | $2.54 |
| AVG Volume (30 Days) | 1.3M | ★ 16.5M |
| Earning Date | 11-13-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16.01 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $2.62 | $1.07 |
| 52 Week High | $8.64 | $3.44 |
| Indicator | ACHV | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 44.06 | 59.96 |
| Support Level | $5.96 | $1.24 |
| Resistance Level | $7.30 | $2.73 |
| Average True Range (ATR) | 0.38 | 0.25 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 43.93 | 62.82 |
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.